|  | Digital Pharma East
October 18-20, 2022 | Philadelphia, PA Explore how life science companies can augment their marketing and commercialization efforts and deliver improved value to customers by leveraging digital channels and technologies. Register Now! |
|---|
Featured Story | By Max Bayer Legend has scrapped phase 1 plans for one of its early-stage CAR-T therapies six weeks after the FDA lifted a clinical hold on the trial. The move comes as the company is looking to prove it's not just a one-hit-wonder following the approval of Carvykti. read more |
| |
|---|
|
Top Stories By James Waldron In a case of biotech-on-biotech M&A action, Portage Biotech will acquire Tarus Therapeutics and its haul of adenosine receptor antagonists. read more By Nick Paul Taylor CytomX Therapeutics is pulling the plug on its lead candidate after getting a look at phase 2 data. One of the arms hit its primary endpoint but the data fell short of the bar CytomX set for further development, leading it to halt work and seek a partner for the prospect. read more Sponsored By: Parexel The rise of clinical trial complexity has been well-documented but the impact on logistics is not well understood. Here, we look at decentralized trials, patient experience and the role of logistics. read more By James Waldron Applied Molecular Transport’s stock crashed down to earth this morning as the biotech’s inflammatory bowel disease drug failed to beat Humira in a phase 2 trial in ulcerative colitis. read more By Gabrielle Masson Kernal Biologics has bagged $25 million to advance its oncology messenger RNA (mRNA) tech, with backing from Big Pharma Amgen—and a former Bristol Myers Squibb leader joining the biotech’s exec team. read more By Conor Hale Using its artificial intelligence programs, Insilico Medicine said it has identified more than a handful of previously untapped genomic targets that could provide avenues to new treatments for amyotrophic lateral sclerosis and potentially rescue patients from the neurodegenerative effects of the disease better known as ALS. read more By Kevin Dunleavy The FDA has tweaked its emergency use authorization for Pfizer’s COVID-19 antiviral Paxlovid, allowing pharmacists to provide the antiviral treatment to those who have been recently infected and are at risk for progressing to a severe form of the virus. The adjustment will allow greater access to the medicine. read more By Gareth Macdonald Latin America is an opportunity for the decentralized trial sector, according to Care Access, which is putting its money where its mouth is with the acquisition of a study unit in Brazil. read more By Robert King A study published in Health Affairs found a majority of mental health providers don't see Medicaid patients in Oregon despite being on managed care directories. read more By Angus Liu Weeks after speculation surrounding a potential Merck acquisition of Seagen first surfaced, the two companies are now reportedly nearing a deal that could be the biopharma world’s largest since 2020—unless antitrust regulators intervene. read more By Robert King Senate Democrats released a deal Wednesday aimed at giving Medicare the power to negotiate for lower drug prices and include inflationary caps on Medicare drug costs. read more By Fraiser Kansteiner More details have emerged surrounding Lotte Group’s gung-ho push into the contract manufacturing arena, which first kicked off in May with the purchase of a Bristol Myers Squibb manufacturing plant in East Syracuse, New York. read more |  | New Product Planning Summit September 19-20, 2022 | Boston, MA Join us for the ONLY conference for defining how the new product planning role and related functions make informed, value-based, data-driven decisions about products in the pipeline. Register now! |
|---|
Resources Sponsored by: Catalent Pharmaceutical drug developers continue to realize the strong therapeutic potential of highly potent active pharmaceutical ingredients (HPAPIs). This is particularly true for therapeutic areas such as oncology, where highly potent drugs are becoming more commonplace. Sponsored by: Lumanity Check out our 22 on-demand panels, featuring 100+ speakers. Tap into discussions of scientific progress in oncology around development, regulatory, clinical, commercial and investment perspectives. Sponsored by: Catalent Pharmaceutical development companies face several challenges when developing orally bioavailable formulations of active pharmaceutical ingredients. Up to 70% of new drug molecules are poorly soluble in gastrointestinal fluids and can exhibit poor absorption across the gut wall. Sponsored by: Cognizant Explore how Cognizant SIP helped Roche streamline its global feasibility process. Sponsored by: Blue Matter Consulting For an emerging biopharma company, Europe can be very attractive. But it can also be complex and confusing. This e-book covers the 12 most common pitfalls for companies entering European markets for the first time, offering guidance to help growing companies avoid them and succeed. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Thermo Fisher Scientific Sponsored by Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals. Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: CG Life Explore the new cell therapy handbook from Thermo Fisher Scientific. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? | 
